Stable, Concentrated Radionuclide Complex Solutions
Patent No. EP4541379 (titled "Stable, Concentrated Radionuclide Complex Solutions") was filed by Advanced Accelerator Applications on Sep 25, 2018. The application was issued on Nov 19, 2025.
Patent Summary
A process for manufacturing a pharmaceutical aqueous solution involves forming a complex of $^{177}\text{Lu}$ and DOTA-TATE. This is achieved by mixing an aqueous $^{177}\text{Lu}$ solution with an aqueous DOTA-TATE solution containing a first stabilizer (gentisic acid, ascorbic acid, or their salts) and heating the mixture. The resulting complex solution is then diluted with an aqueous dilution solution containing a second stabilizer (gentisic acid, ascorbic acid, or their salts). The final pharmaceutical aqueous solution contains less than 5% ethanol by weight (w/w%), provides a radioactive dose of 7.4 GBq, and has a total volume between 20.5 and 25.0 mL. The solution is designed for high chemical and radiochemical stability for the treatment of neuroendocrine tumors.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4541379
- Application Number
- EP25162390A
- Filing Date
- Sep 25, 2018
- Status
- Granted And Under Opposition
- Oct 17, 2025
- Publication Date
- Nov 19, 2025
- External Links
- Slate, Register , Google Patents